Pharmaceutical

BMS Schizophrenia Adjunct Therapy Cobenfy Phase III Trial Results Fail BMS Bristol Myers Squibb's Phase III ARISE trial of Cobenfy as adjunctive therapy for schizophrenia did not meet its primary endpoint but showed encouraging trends and a consistent safety profile.
NIH Cuts and the Future of U.S. Biopharma NIH Biopharmaceutical Trump's proposed NIH budget cuts, agency consolidations, and funding restrictions could reshape U.S. biomedical research, strain U.S.-China collaborations, and shift national priorities toward AI and space tech.
Sanofi: Potential Super Heavy Bomb Stumbles Sanofi Sanofi's Amlitelimab, an OX40L monoclonal antibody, stumbles in asthma trials. With a strong potential in atopic dermatitis, this drug faces competition from Dupixent. OX40's future in autoimmune diseases remains promising despite challenges.
$345 Million Deal: Boehringer Ingelheim and Cue Biopharma Launch New Era in Autoimmune Disease Treatment Boehringer Ingelheim Boehringer Ingelheim partners with Cue Biopharma in a $345M deal to develop CUE-501, a next-gen bispecific antibody therapy targeting autoimmune diseases with precision and improved safety.
Top 10 Oncology Products by Global Sales in 2024 Oncology Market Trend Merck Roche AstraZeneca Explore the top 10 global oncology drugs of 2024 by sales. Discover leading therapies like Keytruda and Darzalex, modality trends, solid vs. blood tumor market insights, and the growing role of cell and gene therapies.
Global Biopharma Layoffs April 2025 Layoffs Pfizer Gilead Stay updated on recent global biopharma layoffs in April 2025. Learn about job cuts, restructuring plans, and the latest industry developments across leading biotech and pharma companies.
Johnson & Johnson's Q1 2025 Financial report Johnson & Johnson Market Trend Financial statements Johnson & Johnson's Q1 2025 report shows a 135% sales surge for CARVYKTI, a CAR-T therapy co-developed with Legend Biotech, with projected annual sales hitting $2B. Oncology drug sales also saw strong growth.
Nuclear Medicine Titans: The Battle in a $10 Billion Market Bayer Novatis AstraZeneca BMS Eli Lilly Explore how pharma giants like Novartis, Bayer, AstraZeneca, BMS, and Eli Lilly are battling for dominance in the booming $10B radiopharmaceutical market with cutting-edge therapies and strategic acquisitions.
Gene Therapy IND Overview (Jan-Mar) 2025 Market Trend Hengrui A comprehensive overview of global gene therapy IND approvals from January to March 2025, highlighting breakthroughs in rare diseases, neurological disorders, and innovative delivery platforms.
mRNA Vaccine Progress Review (January–March) 2025 Market Trend mRNA Roche CSPC Explore key mRNA vaccine developments from Jan–Mar 2025, covering breakthroughs in cancer, flu, herpes zoster, and tuberculosis prevention and treatment globally.